ABSTRACT BACKGROUND: Lyme borreliosis (LB) is the most prevalent arthropod-borne infectious disease in North America. Currently, no vaccine is available to prevent LB in humans, although monovalent and multivalent vaccines have been developed in the past.
Both vaccines underwent large Phase III clinical trials with over 10 000 subjects each and produced promising outcomes. 8, 9 Both
ImmuLyme and LYMErix exhibited moderate efficacy (49%-68%) in the first year with high efficacy (83%-92%) following a booster dose. 8, 9 However, FDA approval in 1998 was sought only for LYMErix. 8, 12 Following the introduction of LYMErix, it was suspected that molecular mimicry between the human lymphocyte functionassociated antigen-1 (hLFA-1) adhesion molecules and B. burgdorferiOspA was contributing to the development of antibody-mediated arthritogenesis. 13 The sequence similarities between OspA and hLFA-1, particularly in patients with HLA-DR4, was thought to be the underlying mechanism of progression to the persistent form of LB observed in a small percent of patients. [13] [14] [15] Indeed, HLA-DR4 and HLA-DR2 alleles were previously linked to chronic Lyme arthritis in LB cases. 16 This led to questioning the safety of using LYMErix in patients with HLA-DR4 allele being based on OspA antigen. Further investigation led to two reports suggesting the development of chronic arthritis in a hamster model and four human cases. 17, 18 These indications -although not corroborated against the safety of LYMErix by the FDA -together with its slow acceptance due to high cost, the extensive anti-vaccination campaigns, the complicated administration schedules and the failure to identify populations at risk of infection, all resulted in its voluntary withdrawal from the market in 2002 together with its licence. [7] [8] [9] [10] [11] More recently, Baxter BioScience developed a second-generation multivalent vaccine against LB with a purpose of global application. 7, 19 Although B. burgdorferi sensu stricto causes Lyme disease in North America, several other pathogenic strains are found across Europe and worldwide. The new trial-vaccine, therefore, was comprised of three chimeric OspA protective epitopes of B. burgdorferi, B. afzelii, B. garinii and B. bavariensis which are intended to prevent the possibility of molecular mimicry and induce potent antibody responses against all major Borrelia species. 19 Safety and immunogenicity evaluation of that vaccine were recently conducted through Phase I/II dose-finding studies in adult populations. 19, 20 Despite the increasing prevalence of LB in North America, Europe and Asia, there is currently no vaccine available to prevent the transmission of B. burgdorferi from the tick to humans. Future development of a safe, potent, well-tolerated and cost-effective vaccine would entail evaluating the past vaccine approaches, strategies and effectiveness. 7, 21 The current study quantitatively and qualitatively assesses the safety, immunogenicity and efficacy profiles of the monovalent and multivalent LB vaccines from the available clinical trials, in the hope this may assist in the development of future vaccines for the human disease. The outcome of this study may permit establishing a benchmark relationship between immunogenicity of the older vaccines and their clinical efficacy. This will allow for inferring the expected utility of immunogenicity of newer vaccines as a surrogate endpoint for their efficacy.
METHODS

Search strategy and selection criteria
A search was conducted in PubMed, Ovid MEDLINE, and Embase databases to the last week of January 2016 using the search terms (MeSH) "vaccine", "vaccination", "Lyme disease/Borreliosis", "clinical trial(s)" and "efficacy". When we limited the search to English language (since no clinical trials were published in other languages) and studies in human subjects, the search resulted in 72 articles that were selected for title and abstract review. After removing duplicates and excluding reports published as review articles, letters, case studies, editorials, conference abstracts, and animal studies, only 11 articles were considered for full text review. Full article review resulted in the further exclusion of four reports that were only in children (as we focused on adult population because initial licensure of most vaccines was for use in adults), assessed the effect of booster vaccine doses, or evaluated the effect of vaccine on disease serological testing (see Figure 1) . A total of seven peer-reviewed articles on the monovalent LYMErix 9,22,23 and
ImmuLyme vaccines 8, 24 and the multivalent novel vaccine 19, 20 were identified for the current study.
Inter-reviewer agreement
The abstracts of the identified studies were independently reviewed by two readers (SH and MS). Differences were resolved through discussions so that a consensus could be reached. Percentage agreement and Cohen's Kappa (κ) statistic 25 were calculated and interpreted in accordance with Landis and Koch's benchmarks 
Data extraction
Data extracted from the selected studies included the first author's name, publication date, trial type, recruitment dates, vaccine type, dose schedule, dose level in μg, number of subjects, sex ratio (M:F), age, and the study outcome (Table 1) . Moreover, the percentage of solicited and unsolicited, local and systemic adverse effects were extracted for both monovalent and multivalent vaccines (Table 2) together with information on the seropositivity rates of IgG antiOspA levels (in enzyme-linked immunosorbent assay (ELISA) units; ELU/mL) in vaccinated subjects (Table 3) . To determine the rates of immunogenicity (%) in the vaccinated subjects, meta-analysis of percentage of subjects positive for the IgG anti-OspA (and 95% CIs) were calculated from the identified studies for the initial and final dose schedules. Percentage of subjects with 1400 and 5000 ELU/mL for the monovalent and multivalent vaccines, respectively, was used as a cut-off point for IgG as these levels were proposed to ensure a protection for one tick season. 19, 20, 22, 23 Since no Phase III clinical trials were conducted for the multivalent vaccine, data on the vaccine initial, final and overall efficacy were only available for the monovalent vaccines 8,9,24 ( Figure 2 ).
Data analysis
The primary outcome measure was to compare the reactogenicity and immunogenicity between the monovalent and multivalent vaccines from the results of the available clinical trials. Metaanalyses were carried out for the local and systemic side effects as well as the percent seropositivities of the two vaccine classes. We used a binary random-effects model since we assumed that the vaccination for LB can vary across populations. Odds ratio (OR) and 95% confidence intervals (95% CI) were also evaluated for the REVIEW OF LYME DISEASE VACCINES EFFICACY LB risk in vaccinated people at the initial and final dose schedules as well as the overall protection following vaccination with the monovalent vaccine ( Figure 2 ). Meta-analysis tests were conducted using the OpenMeta Analyst version 10.10, a free, cross-platform, open-source program. 27 Weighted average of efficacy was calculated at each vaccination stage from the reported efficacy results of the individual studies. To assess whether there is true heterogeneity among the three selected studies, 8, 9, 24 we used the Q test. 28 Q test only informs about the presence versus the absence of heterogeneity and does not report on the extent of such heterogeneity. Therefore, we calculated the I 2 index to complement the Q test and quantify the degree of heterogeneity among studies. 29 Given the poor power of Q test to detect true heterogeneity among this small number of studies, we also quantified the true heterogeneity by estimating the between-study variance in the random-effects model (τ 2 ) as previously described. 30 A p-value < 0.05 was considered to be statistically significant. Forest plots were used to illustrate the OR of LB following vaccination from the selected studies and to inspect the heterogeneity of the individual findings ( Figure 2 ).
RESULTS
The monovalent adjuvant vaccines LYMErix and ImmuLyme and the multivalent vaccine were evaluated in several studies, as shown in Table 1 . The clinical trials were Phase III double-blind, placebocontrolled or open-label, randomized trials for the monovalent vaccines to assess their efficacy, safety and immunogenicity. On the other hand, the multivalent vaccine was evaluated only through double-blind, randomized, Phase I/II trials that also included a dose-escalation schedule and were limited to assess the vaccine reactogenicity and immunogenicity. The number of the examined subjects varied from 300 to 10 936 in the seven identified studies. Given the nature of the clinical studies, i.e., Figure 1 . Systematic literature review process. The flow diagram describes the systematic review of literature on the adverse effects, immunogenicity and efficacy of Lyme borreliosis monovalent and multivalent vaccines. The additional record was identified from an initial pre-study literature search. A total of seven unique clinical trials were identified from the total of 64 examined titles.
Phase I/II vs. Phase III trials, the number of participants in the monovalent vaccines trials (n = 12 292 for LYMErix and 11 939 for ImmuLyme, total n = 24 231) was significantly higher than that in the multivalent vaccine trials (n = 650). The sex ratio of the participants in all clinical trials was 1.23 (M:F). The average age of the participants in the individual trials ranged from 31 to 51 years with an overall age range of 15 to 79 years.
Dose levels and schedules
A common vaccine administration schedule from the identified trials to provide an effective protection for one tick season was 0, 1 and 12 months. 8, 9, [22] [23] [24] However, to evaluate a different dosage schedule that may lead to a better protection, a few studies compared the safety and immunogenicity profiles for LYMErix 22, 23 and the multivalent vaccine 20 at either shorter (<6 months) dose schedule 20, 22 or with more than three doses within a 12-month period. 19, 20, 23 The identified studies primarily evaluated the effect of a dose level of 30 μg for both the monovalent and multivalent vaccines ( Table 1) . Phase I/II trials for the multivalent vaccine also explored the effect of higher dose levels of 60 and 90 μg.
19,20
Increasing the dose from 30 to 60 or 90 μg did not result in higher rates of reactogenicity or significant improvement in seropositivity (data not shown). Therefore, only the 30 μg dose level was included in the meta-analysis to compare the monovalent and multivalent vaccines for the percentages of incidence of local and systemic, solicited and unsolicited adverse effects (Table 2 ) and their immunogenicity depicted by the seropositivity rates of IgG anti-OspA levels (Table 3) .
Safety and reactogenicity
The percentage incidence of adverse effects in the study subjects who received 30 μg monovalent and multivalent vaccines is shown in Table 2 . Among the local adverse effects, incidence of redness in individuals who received multivalent vaccines was 6.8-fold significantly lower than in those administered the monovalent LYMErix or ImmuLyme (2.6%, 95% CI: 0.0%-5.1% vs. 17.7%, 95% CI: 5.4%-30.1%; p < 0.05). Similarly, individuals who received the multivalent vaccine exhibited 2.9-fold lower incidence of fever compared to those administered the monovalent ones (0.7%, 95% CI: −0.6% to 1.8% vs. 2.0%, 95% CI: 1.6%-2.3%; p < 0.05). The incidences of other local and systemic adverse effects, such as site pain, swelling, tenderness, arthralgia, fatigue, headache, malaise and myalgia, were lower in the multivalent vaccinated subjects compared to in those who received the monovalent vaccines, although these differences were not statistically significant, probably due to the small number of evaluated studies and the large difference in effect size between the two vaccines. For example, swelling occurred in 0.6%-16% of the cases in response to monovalent vaccines compared to 0%-3% in response to the multivalent vaccine. Similarly, site pain was observed in 15%-70% of the subjects who received the monovalent vaccines compared to incidences of 6%-42% in those who received the multivalent vaccine.
Immunogenicity
Subjects vaccinated with the monovalent or multivalent vaccines and who developed anti-OspA IgG antibody titers of ≥1400 22, 23 or ≥5000 ELU/mL, 19, 20 respectively, were considered seroprotected for Overall, the seropositivity rates of IgG anti-OspA levels that ensured protection for one tick season were comparable between the monovalent and multivalent vaccines at both the initial and final dose schedules.
Efficacy
Vaccine efficacy in the prevention of human LB was evaluated for the monovalent LYMErix and ImmuLyme vaccines from three Phase III clinical studies 8,9,24 but not for the multivalent vaccine ( Figure 2 ). During the first year, the disease OR was 0.49 (95% CI: 0.14-0.70; p < 0.005 vs. placebo). Following the 12-month final dose, the LB OR improved to 0.31 (95% CI: 0.26-0.63; p < 0.005). The overall disease OR from the three identified clinical trials was 0.4 (95% CI: 0.26-0.63, p < 0.001). The weighted average efficacy of the monovalent vaccines ranged from 56% to 76% for the initial and 12-month final doses, respectively, with an overall weighted average of 65% ( Figure 2 ). The overall vaccination effects displayed a heterogeneity between the effect sizes (χ² test, Q = 6.13, p = 0.047, df = 2). This was also confirmed by an I 2 value of 67.4%, which represent a moderate level of inconsistency between the studies. 31 The source of this effect heterogeneity is primarily due to the large inter-study variation in sample size and the small number of trials being evaluated for two different monovalent vaccines (LYMErix and ImmuLyme).
DISCUSSION
The goals of LB prevention and control are primarily to reduce the number of new cases of the disease and the number of patients experiencing late-stage or persistent conditions, such as posttreatment syndrome. These measures include the reduction of tick host populations, control of tick vectors (ecological and/or chemical), and promoting personal protection of at-risk individuals. 21 Personal protection practices vary from avoidance of tick habitat to using tick or insect repellents and vaccination. Currently, no vaccine is available to prevent LB in humans. The findings from the first (monovalent) and second (multivalent) generation vaccines were promising and can guide the development of novel strategies for future vaccine design. In the late 1990s, the two monovalent LB vaccines LYMErix and ImmuLyme underwent extensive Phase III clinical trials and demonstrated 76% to 92% 8, 9 efficacy after three doses with mildto-moderate local and systemic reactions ( Table 2 ). The success of LYMErix was compromised by non-substantiated claims that it may be associated with autoimmune arthritis (see above).
13-15
A retrospective study of joint complaints following vaccination demonstrated the lack of increased frequency of this adverse event and association between vaccine administration and the onset of symptoms. 32 However, animal studies in dogs did show a causal relationship between vaccination using monovalent preparations and autoimmune destructive arthritis. 33 The current study further validates that monovalent vaccines resulted in mild local solicited and unsolicited side effects in humans with incidence rates ranging from 2.3% to 17.7% 8,9,22,23 with a self-limiting site pain occurrence in 47.6% of the cases ( Table 2 ). The incidence of systemic adverse 11, 32 indicating the safety of the vaccine, LYMErix was voluntarily withdrawn from the market. 12 However, the increasing health burden of LB and its high incidence, together with the reported safety and efficacy of the vaccine, support the need for studies to design and develop another human LB vaccine. 7, 34 A novel approach was considered in a preclinical setting using a single recombinant OspA containing two OspA serotypes (1 and 2), which was shown to induce antibody responses that protected Figure 2 .
Meta-analysis for the efficacy of the monovalent vaccines and their effect on the risk of Lyme borreliosis. Weights are calculated from binary random-effects model analysis. Values represent OR (95% CI) of LB in response to vaccination. Weighted averages (pooled) were calculated for the vaccine efficacy. Heterogeneity analysis was carried out using Q test, the among-studies variation (I 2 index) and between-study variance in the random-effects model (τ 2 ) at the initial, final and overall dosing schedules.
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mice against infection with both B. burgdorferi (OspA-1) and Borrelia afzelii (OspA-2). 35 The new vaccine was designed to provide protection against almost all B. burgdorferi strains linked to human LB worldwide. The vaccine contained protective epitopes from the six OspA serotypes 1-6 where the risk of T-cell crossreactivity is eliminated by replacing the putative cross-reactive OspA-1 epitope with the corresponding OspA-2 sequence. 19 As mentioned above, this vaccine offered protection in immunized mice against infection with B. burgdorferi, B. afzelii, B. bavariensis and B. garinii. 12 Efficient antibodies were also stimulated against
other Borrelia species such as B. spielmani, B. valaisiania, B. lusitaniae and B. japonica. 7, 12 Most of these other species are minimally pathogenic or non-pathogenic for human. Since B. mayonii is established to be endemic in parts of North America as a cause of human infections, we are not aware of any data about cross protection for this species. A similar method was also presented to allow for the generation of a hexavalent OspA-based vaccine that potentially protects against a wide range of globally distributed Borrelia species causing LB. 36 Phase I/II dose finding studies for the multivalent vaccine were initiated to examine its safety and immunogenicity in a healthy adult population. 19 These clinical trials were extended to investigate the tolerability and immunogenicity of the vaccine in individuals who have been previously infected with B. burgdorferi (seropositive) and in seronegative adults and evaluated the longevity of the antibody response maintained through the tick season. It also evaluated the requirement for additional booster immunizations. 20 The monovalent vaccines suffered from poor durability of protection. This outcome cannot be concluded for the multivalent vaccines since Phase III clinical trials are yet to be undertaken. Indeed, it might be difficult to compare safety and immunogenicity data reported for different studies. However, based on the results of the current study and others, 12 it is reasonable to suggest that the multivalent vaccine is as well tolerated and highly immunogenic as the earlier monovalent ones (Table 2 ). In the Phase I/II study of the multivalent vaccine, 19, 20 some solicited and unsolicited local and systemic reactions occurred at a lower rate by alum-adjuvanted formulations than reported for the Phase III study of the monovalent vaccine. 8, 9, 24 For example, the incidences of local adverse effects such as redness and systemic side effects such as fever were, respectively, 6.8-and 2.9-fold significantly lower in subjects who received the multivalent vaccine compared to their counterparts who were administered the monovalent vaccines.
Although not statistically significant, the incidences of other local and systemic adverse effects reported for the two vaccine types were lower in the multivalent vaccinated subjects than in those who received the monovalent vaccines. The slight improvement in the reactogenicity of the multivalent vaccine compared to the monovalent ones may be related to the absence of the molecular mimicry between hLFA-1 and OspA that was present in the the first generation monovalent vaccines -and compromised their success -when cross-reactive OspA-1 epitope was replaced by the corresponding OspA-2 sequence in the second generation multivalent vaccines. 19 Furthermore, the percentage of vaccinated subjects who were seropositive for IgG anti-OspA at levels that ensure protection for one tick season was comparable between the two vaccine types at both the initial and final vaccination stages (Table 3) . It should be highlighted, however, that the smaller sample size in the Phase I/II study compared to Phase III trials may preclude definitive conclusion as to whether this lower reactogenicity and similar immunogenicity of the multivalent vaccine compared to the monovalent vaccines represent a statistically significant better tolerability or merely reflect a sampling bias. 12, 37 The efficacy of the monovalent vaccines in the prevention of LB was evaluated in three clinical trials. 8, 9, 24 During the first year, the disease OR was 0.49 (95% CI: 0.14-0.70; p < 0.005) and improved to 0.31 (95% CI: 0.26-0.63; p < 0.005) following the 12-month booster dose with an overall disease OR of 0.4 (95% CI: 0.26-0.63, p < 0.001). The weighted average efficacy of the monovalent vaccines was 56% and 76% for the initial and 12-month final dose schedules, respectively, with an overall efficacy of 65% (Figure 2 ). Based on the comparable tolerability and immunogenicity between the monovalent and multivalent vaccines, it can be expected that the latter will result in a similar, if not an improved, efficacy against human LB. Based on the promising findings of the Phase I/II trials, 19, 20 Phase III efficacy trials of the multivalent vaccine were expected from Baxter BioScience. 12, 23 However, these studies are stalled and yet to be Although successfully constituting the first systematic review on the efficacy and reactogenicity of the monovalent and multivalent Lyme disease vaccines, the current study has a number of limitations. The limited number of trials for each vaccine, together with the large between-studies variation in the effect size both for local and systemic adverse effects, rendered a thorough comparison between the two vaccine types inconclusive. Furthermore, the lack of Phase III trials for the multivalent vaccines did not permit for evaluating the comparative efficacies between the monovalent and multivalent vaccines.
The multivalence nature of the new vaccine, the absence of the molecular mimicry between hLFA-1 and OspA, and the reduced overall reactogenicity compared to the monovalent vaccines, all suggest a promising turnover for the multivalent vaccine if further developed. However, it was argued that a minimum of safety data about the new vaccine were presented and that a simple replacement of a vaccine with another that has the same problems and approach may not be the proper course for a new vaccine development. 39 New strategies for the development of an effective LB vaccine are currently under extensive evaluation 7, 21, 34, 36, 40 and they are based primarily on the fact that B. burgdorferi spirochetes when transmitted by ticks utilizes a tick protein to stabilize the host infection. 40 These approaches included immunization with a cocktail of several B. burgdorferi Osps (e.g., OspB, OspC, OspF and DbpA); employment of tick salivary proteins to modulate host immune responses (e.g., Th-1 response); use of tick proteins to induce an immune response at the site of tick bite or interfere with other host defense responses (e.g., coagulation system); or immunization with a combination of tick protein and B. burgdorferi Osps. 7, 35 In general, future development of an effective vaccine against Borrelia was proposed to be based on a combination of vaccinogenic factors consisting of multiple Borrelia antigens, antigens of ticks, or a combination of both to elicit a synergistic immune response against the bacteria and the tick. 21 This promising direction might not only be applicable for the prevention of transmission of B. burgdorferi from the tick to the host but could also prove instrumental in the prevention of transmission of other vector-borne pathogens. Whether this approach is considered, or further development of the multivalent vaccine is undertaken, the new vaccine must be characterized by higher safety standards, improved efficacy, lower cost and enhanced public acceptance compared to the previous generation of the monovalent vaccines. In addition to incorporating all major Borrelia species, the new vaccine should also take into consideration the recent identification of the novel pathogenic species causing LB with high spirochaetaemia (B. mayonii). 41 Last, data on cost-effectiveness of monovalent vaccine suggest that the vaccine was not cost effective outside high incidence areas. 42 
